CA2442012A1 - Derives chimiques et leur application comme agent antitelomerase - Google Patents

Derives chimiques et leur application comme agent antitelomerase Download PDF

Info

Publication number
CA2442012A1
CA2442012A1 CA002442012A CA2442012A CA2442012A1 CA 2442012 A1 CA2442012 A1 CA 2442012A1 CA 002442012 A CA002442012 A CA 002442012A CA 2442012 A CA2442012 A CA 2442012A CA 2442012 A1 CA2442012 A1 CA 2442012A1
Authority
CA
Canada
Prior art keywords
alkyl
radical
amino
optionally substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002442012A
Other languages
English (en)
French (fr)
Inventor
Patrick Mailliet
Abdelazize Laoui
Jean-Francois Riou
Gilles Doerflinger
Jean-Louis Mergny
Francois Hamy
Thomas Caulfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/fr
Application filed by Individual filed Critical Individual
Publication of CA2442012A1 publication Critical patent/CA2442012A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002442012A 2001-03-23 2002-03-22 Derives chimiques et leur application comme agent antitelomerase Abandoned CA2442012A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (fr) 2001-03-23 2001-03-23 Derives chimiques et leur application comme agent anti-telomerase
FR01/03916 2001-03-23
FR0110370 2001-08-02
FR01/10370 2001-08-02
PCT/FR2002/001005 WO2002076975A1 (fr) 2001-03-23 2002-03-22 Derives chimiques et leur application comme agent antitelomerase

Publications (1)

Publication Number Publication Date
CA2442012A1 true CA2442012A1 (fr) 2002-10-03

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002442012A Abandoned CA2442012A1 (fr) 2001-03-23 2002-03-22 Derives chimiques et leur application comme agent antitelomerase

Country Status (11)

Country Link
EP (1) EP1373252A1 (enExample)
JP (1) JP2004524349A (enExample)
AR (1) AR034297A1 (enExample)
AU (1) AU2002251140B2 (enExample)
CA (1) CA2442012A1 (enExample)
CO (1) CO5380035A1 (enExample)
IL (2) IL158056A0 (enExample)
MX (1) MXPA03008269A (enExample)
MY (1) MY130957A (enExample)
PE (1) PE20020959A1 (enExample)
WO (1) WO2002076975A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2608463C (en) * 2005-05-19 2015-02-03 Prometic Biosciences Inc. Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
KR20100038108A (ko) * 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
FR2948686B1 (fr) * 2009-07-30 2011-08-19 Biomerieux Sa Nouveaux substrats de peptidase
US20210024455A1 (en) * 2018-03-20 2021-01-28 Hiroshima University Compound which inhibits telomere-binding protein, and telomere-binding protein inhibitor containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
IL149402A0 (en) * 1999-11-29 2002-11-10 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
AU2003244463A1 (en) * 2002-02-05 2003-09-02 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative

Also Published As

Publication number Publication date
IL158056A0 (en) 2004-03-28
IL158056A (en) 2010-02-17
JP2004524349A (ja) 2004-08-12
AU2002251140B2 (en) 2007-03-15
AR034297A1 (es) 2004-02-18
MY130957A (en) 2007-07-31
MXPA03008269A (es) 2004-10-15
PE20020959A1 (es) 2002-12-17
EP1373252A1 (fr) 2004-01-02
CO5380035A1 (es) 2004-03-31
WO2002076975A1 (fr) 2002-10-03

Similar Documents

Publication Publication Date Title
JP7240784B2 (ja) ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物
EP1244650B1 (fr) Derives arylamines et leur application comme agent antitelomerase
JP5739820B2 (ja) 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
KR20220092920A (ko) 헬리오스의 소분자 분해제 및 사용 방법
JP2017190337A (ja) がんを処置するための組合せ治療
CN107635965A (zh) 用于治疗淋巴瘤的ezh2抑制剂
CA2442012A1 (fr) Derives chimiques et leur application comme agent antitelomerase
JP6846574B2 (ja) スルホンアミド化合物およびその使用
HUE034807T2 (en) New quinoline-substituted compound
JP2018513865A (ja) 癌を処置するための併用療法
CN111566095A (zh) 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
CA2973773A1 (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
CN115043817A (zh) Sos1蛋白水解调节剂及其制备方法和应用
FR2850970A1 (fr) Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
CN118019743A (zh) 可用作shp2抑制剂的化合物及其制备方法和用途
CN114206864B (zh) 喹唑啉-2.4-二酮衍生物作为parp抑制剂
AU2022224918A1 (en) Novel pyrazole derivatives
JPH0753376A (ja) 強迫疾患の治療用医薬を製造するためのｎ−（ピリジニル）−１ｈ−インドール−１−アミンの使用
KR20240009422A (ko) Sting 시그널링의 소분자 억제제 조성물 및 사용 방법
AU2018379438A1 (en) Imidazopyridine derivatives and the use thereof as medicament
WO2019154133A1 (zh) 二噁烷并喹啉类化合物及其制备方法与应用
CN114957235A (zh) 苯并噻嗪酮衍生物及其制备方法和用途
CN110862398B (zh) 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
CA2433723A1 (fr) Derives chimiques et leur application comme agent antitelomerase

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued